MSD’s Q2 2022 earnings report

July 28, 2022

Share this article

article hero thumbnail

MSD’s Q2 2022 results deliver robust sales growth and important clinical advancements. The company announced Q2 worldwide sales of $14.6 billion, an increase of 28% from Q2 2021.

“I continue to be immensely proud of how the MSD team is performing in all facets of our business – scientifically, commercially and operationally,” said Robert M. Davis, chief executive officer and president. “Our strategy is working and our future is bright. I am very confident that we are well-positioned to achieve our near- and long-term goals, anchored by our commitment to deliver innovative medicines and vaccines to patients and value to all of our stakeholders, including shareholders.”

MSD anticipates full-year 2022 worldwide sales to be between $57.5 billion and $58.5 billion.

Take a look at the infographic below for more details.

Download infographic

primary article image